Muzaffar Abbas1, Sami Alzarea1, Roger L Papke2, Shafiqur Rahman3. 1. Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, SD, USA. 2. Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA. 3. Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, SD, USA. Electronic address: Shafiqur.Rahman@sdstate.edu.
Abstract
BACKGROUND: Previous studies have shown that α7 nicotinic acetylcholine receptor (nAChR) has a critical role in the regulation of pain sensitivity and neuroinflammation. However, pharmacological effects of α7 nAChR activation in the hippocampus on neuroinflammatory mechanisms associated with allodynia and hyperalgesia remain unknown. We have determined the effects of 3a,4,5,9b-tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS), an α7 nAChR positive allosteric modulator, on lipopolysaccharide (LPS)-induced allodynia and hyperalgesia in mice. We also evaluated the effects of TQS on immunoreactivity of microglial marker ionized-calcium binding adaptor molecule 1 (Iba-1), phospho-nuclear factor-κB (p-NF-κB p65), tumor necrosis factor-alpha (TNF-α), and norepinephrine (NE) level. METHODS: Mice were treated with (0.25, 1 or 4 mg/kg, ip) followed by LPS (1 mg/kg, ip) administration. Allodynia and hyperalgesia were determined using von Frey filaments and hot plate respectively. Immunoreactivity of Iba-1, p-NF-κB p65, and TNF-α, were measured in the hippocampus using immunofluorescence assay. Hippocampal NE level was evaluated using high performance liquid chromatography. RESULTS: LPS administration resulted in allodynia and hyperalgesia in mice after six h. Systemic administration of TQS prevented LPS-induced allodynia and hyperalgesia. TQS pretreatment significantly decreased the immunoreactivity of Iba-1, p-NF-κB, and TNF-α in CA1 and DG regions of the hippocampus. In addition, TQS reversed LPS-induced NE reduction in the hippocampus. CONCLUSIONS: Taken together, our results suggest that TQS prevented LPS-induced allodynia and hyperalgesia, upregulation of TNF-α expression and NE level reduction involving microglial α7 nAChR in part in the hippocampus. Therefore, these findings highlight the important effects of α7 nAChR allosteric modulator against symptoms of inflammatory pain.
BACKGROUND: Previous studies have shown that α7 nicotinic acetylcholine receptor (nAChR) has a critical role in the regulation of pain sensitivity and neuroinflammation. However, pharmacological effects of α7 nAChR activation in the hippocampus on neuroinflammatory mechanisms associated with allodynia and hyperalgesia remain unknown. We have determined the effects of 3a,4,5,9b-tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS), an α7 nAChR positive allosteric modulator, on lipopolysaccharide (LPS)-induced allodynia and hyperalgesia in mice. We also evaluated the effects of TQS on immunoreactivity of microglial marker ionized-calcium binding adaptor molecule 1 (Iba-1), phospho-nuclear factor-κB (p-NF-κB p65), tumor necrosis factor-alpha (TNF-α), and norepinephrine (NE) level. METHODS:Mice were treated with (0.25, 1 or 4 mg/kg, ip) followed by LPS (1 mg/kg, ip) administration. Allodynia and hyperalgesia were determined using von Frey filaments and hot plate respectively. Immunoreactivity of Iba-1, p-NF-κB p65, and TNF-α, were measured in the hippocampus using immunofluorescence assay. Hippocampal NE level was evaluated using high performance liquid chromatography. RESULTS:LPS administration resulted in allodynia and hyperalgesia in mice after six h. Systemic administration of TQS prevented LPS-induced allodynia and hyperalgesia. TQS pretreatment significantly decreased the immunoreactivity of Iba-1, p-NF-κB, and TNF-α in CA1 and DG regions of the hippocampus. In addition, TQS reversed LPS-induced NE reduction in the hippocampus. CONCLUSIONS: Taken together, our results suggest that TQS prevented LPS-induced allodynia and hyperalgesia, upregulation of TNF-α expression and NE level reduction involving microglial α7 nAChR in part in the hippocampus. Therefore, these findings highlight the important effects of α7 nAChR allosteric modulator against symptoms of inflammatory pain.
Authors: Deniz Bagdas; Jenny L Wilkerson; Abhijit Kulkarni; Wisam Toma; Shakir AlSharari; Zulfiye Gul; Aron H Lichtman; Roger L Papke; Ganesh A Thakur; M Imad Damaj Journal: Br J Pharmacol Date: 2016-07-18 Impact factor: 8.739
Authors: Tracey A Ignatowski; Reeteka Sud; Jessica L Reynolds; Paul R Knight; Robert N Spengler Journal: Neuropharmacology Date: 2005-01-25 Impact factor: 5.250
Authors: William C Covey; Tracey A Ignatowski; Amy E Renauld; Paul R Knight; Nader D Nader; Robert N Spengler Journal: Reg Anesth Pain Med Date: 2002 Jul-Aug Impact factor: 6.288
Authors: Zulkifal Malik; Muzaffar Abbas; Lina Tariq Al Kury; Fawad Ali Shah; Mahboob Alam; Arif-Ullah Khan; Humaira Nadeem; Saad Alghamdi; Muhammad Umar Khayam Sahibzada; Shupeng Li Journal: Drug Des Devel Ther Date: 2021-02-04 Impact factor: 4.162